Participants in the Riyadh Global Biomedical Technology Summit underlined the need to launch an international coalition to work on the implementation of a set of recommendations issued at the end of the two-day conference.
Held under the auspices of Crown Prince Mohammad bin Salman, the Riyadh International Biomedical Technology Summit concluded on Thursday, with the participation of a large number of government officials, experts and scientists in biomedical technology.
The conference emphasized the importance of maximizing health technology investment and cell and gene therapy, as well as researching ways to eliminate solid tumors by targeting cancer cells using cell therapy, and improving research and development productivity.
Bandar Al-Khorayef, Saudi Minister of Industry and Mineral Resources, said that the Kingdom followed a strategic and comprehensive approach to building the right infrastructure for biotechnology on a global level, with the aim to attract the best talents, promote innovation, and turn Saudi Arabia into an international leader in the field of healthcare and life sciences.
The minister added that Saudi Arabia had 50 registered pharmaceutical factories that cover the domestic reserves, with a rate of 28 percent in terms of value, and 42 percent in terms of volume, noting that pharmaceutical exports amounted to 1.5 million riyals ($400,000).
Al-Khorayef emphasized that the chemical pharmaceutical sector in the Kingdom “has proven its efficiency and ability to deal with challenges during the pandemic.”
Eng. Suliman Almazroua, CEO of the National Industrial Development and Logistics Program (NIDLP), touched on the Saudi Vision 2030 programs, which seek to transform the country into a leading industrial power in the world and the region.
The conference sessions discussed clinical trials, the development of the working mechanisms of the Real World Evidence (RWD), and the significant role of the Real World Data and artificial intelligence in reading the present and the assumed future.
